Clinical trial
Anlotinib and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy
NCT03416517 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Anlotinib and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy
- Lead sponsor
- Peking University People's Hospital
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- January 22, 2018
- Completion date
- December 31, 2020
- Enrollment
- 47 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
ewing's tumor metastatic